SCHEMBL6634875

SCHEMBL6634875

CCCN1CCCC2(C1)C(=O)Nc1cccnc12

nearest known ligand 0.41

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 14/20 0.41
HTR1A P08908 12/20 0.41
HTR2A P28223 12/20 0.41
HTR6 P50406 12/20 0.41
OTUD7B Q6GQQ9 5/20 0.37
OPRM1 P35372 1/20 0.36
OPRK1 P41145 1/20 0.36
OPRL1 P41146 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6636284 0.93 HTR7 (0.40) HTR7HTR1AHTR2AHTR6
SCHEMBL6635683 0.82 CALCRL (0.42) HTR7HTR1AHTR2AHTR6
SCHEMBL6634486 0.81 HTR7 (0.44) HTR7HTR1AHTR2AHTR6OPRM1
SCHEMBL6638270 0.81 HTR7 (0.60) HTR7HTR1AHTR2AHTR6OPRM1
SCHEMBL6636447 0.81 HTR7 (0.60) HTR7HTR1AHTR2AHTR6OPRM1
SCHEMBL6635868 0.81 HTR7 (0.60) HTR7HTR1AHTR2AHTR6OPRM1
SCHEMBL6636995 0.81 HTR1A (0.43) HTR7HTR1AHTR2AHTR6
Hydrochloric Acid SCHEMBL6747853 0.81 HTR7 (0.43) HTR7HTR1AHTR2AHTR6OPRM1
Hydrochloric Acid SCHEMBL6635087 0.81 HTR7 (0.43) HTR7HTR1AHTR2AHTR6OPRM1
SCHEMBL6635956 0.80 OTUD7B (0.35) HTR7HTR1AHTR2AHTR6OTUD7B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1426375-A2 Analgesic spiroindole derivatives AstraZeneca AB (SE) 2004-06-09 EP claimed
US-20040087800-A1 Spirooxindole derivatives are analgesics for the treatment of chronic pain. ASTRAZENECA AB 2004-05-06 US claimed
EP-1202994-B1 NEW COMPOUNDS ASTRAZENECA AB (SE) 2004-04-14 EP claimed
EP-1202994-A1 NEW COMPOUNDS AstraZeneca AB (SE) 2002-05-08 EP claimed
WO-2001005790-A1 NEW COMPOUNDS ASTRAZENECA AB (SE) 2001-01-25 WO claimed
US-6774132-B1 Spirooxindole derivatives that act as analgesics ASTRAZENECA AB (SE) 2004-08-10 US disclosed
EP-1426375-A2 Analgesic spiroindole derivatives AstraZeneca AB (SE) 2004-06-09 EP disclosed
US-20040087800-A1 Spirooxindole derivatives are analgesics for the treatment of chronic pain. ASTRAZENECA AB 2004-05-06 US disclosed
EP-1202994-B1 NEW COMPOUNDS ASTRAZENECA AB (SE) 2004-04-14 EP disclosed
EP-1202994-A1 NEW COMPOUNDS AstraZeneca AB (SE) 2002-05-08 EP disclosed
WO-2001005790-A1 NEW COMPOUNDS ASTRAZENECA AB (SE) 2001-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087800-A1 Spirooxindole derivatives are analgesics for the treatment of chronic pain. OPRK1, OPRD1, OPRL1 HTR7 918/4885HTR1A 402/4885HTR2A 1255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.